 |
|
|
| |
Switching From Tenofovir Disoproxil Fumarate and/or Other Oral Antivirals to Tenofovir Alafenamide in Virally Suppressed Chronic Hepatitis B Patients With Moderate or Severe Renal Impairment, or With End-stage Renal Disease on Hemodialysis: Final Week-96 Efficacy and Safety Results From a Phase 2 Open-label Study
|
| |
| |
EASL International Liver Congress, June 23-26, 2021
Harry L.A. Janssen,1 Pietro Lampertico,2 Chien-Hung Chen,3 Jeong Heo,4 Claire Fournier,5 Sang Hoon Ahn,6 Tak Yin Owen Tsang,7 Carla S. Coffin,8 Yi-Hsang Huang,9 Giulio Marchesini,10 Aric Josun Hui,11
Magdy Elkhashab,12 Sayed-Mohammed Jafri,13 Susanna K. Tan,14 Yang Zhao,14 Vithika Suri,14 John F. Flaherty,14 Anuj Gaggar,14 Diana M. Brainard,14 Wan-Long Chuang,15 Kosh Agarwal,16 Edward Gane,17 Young-Suk Lim18
1Toronto Centre for Liver Disease, Toronto General Hospital, University Health Network, Toronto, Ontario, Canada; 2Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Università di Milano, Italy; 3Kaohsiung Chang Gung Memorial Hospital, Kaohsiung City, Taiwan; 4Pusan National University School of Medicine, Pusan National University Hospital, Busan, Republic of Korea; 5Universite de Montreal, Quebec, Canada; 6Yonsei University College of Medicine, Seoul, Republic of Korea; 7Princess Margaret Hospital, Hong Kong; 8University of Calgary, Alberta, Canada;
9Taipei Veterans General Hospital, Taipei City, Taiwan; 10Policlinico S.Orsola-Malpighi, Azienda Ospedaliero-Universitaria di Bologna, Italy; 11Alice Ho Miu Ling Nethersole Hospital, Hong Kong; 12Toronto Liver Centre, Toronto; 13Henry Ford Hospital, Detroit, Michigan, USA; 14Gilead Sciences, Inc., Foster City, California, USA; 15Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung City; 16Kings College Hospital, London, UK; 17Auckland Clinical Studies, Grafton, New Zealand; 18Asan Medical Center, University of Ulsan College of Medicine, Seoul
References: 1. Agarwal K, et al. J Hepatol 2015;62:533-40; 2. Babusis D, et al. Mol Pharm 2013;10:459-66; 3. Lee WA, et al. Antimicrob Agents Chemother 2005;49:1898-906; 4. Murakami E, et al. Antimicrob Agents Chemother 2015;59:3563-9; 5. Lampertico P, et al. EASL 2020, oral 091; 6. Lampertico P, et al. Lancet Gastroenterol Hepatol 2020;5:441-53; 7. Janssen HLA, et al. EASL 2020, poster SAT429. Acknowledgments: We extend our thanks to the patients, their families, and all participating investigators. This study was funded by Gilead Sciences, Inc.
|
| |
|
|
|
|
|
